IQV

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group's “Top 50™ Pharmaceutical Technology Providers” report for 2026. IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA's broad technology cover.

IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

The transaction involved the disposal of 558 shares at an exact weighted-average price of $245.21 per share on July 29, 2026. The sale reduced the insider's direct equity holdings by 16%, leaving 2,989 shares held directly.

The transaction involved the sale of 5,000 shares at $249.16 per share, representing a total value of about $1.2 million. This disposition resulted in a 19% reduction of the insider total direct equity holdings in the company.

The CEO of IQVIA executed an exercise-and-sell of stock appreciation rights involving shares at a weighted average price of $245.51 on July 29, 2026. Bousbib maintains substantial equity exposure through roughly 836,000 directly held shares and about 543,000 shares held indirectly via the Orohena Trust.

IQVIA Holdings Inc. operates behind the scenes, running clinical trials and processing vast healthcare data for pharmaceutical companies. IQV's business spans clinical trial management, healthcare data analytics, software products, and consulting, providing diversified revenue streams. I previously rated IQV a Buy due to strong results and robust demand, but concerns over slowing guidance, CSMS segment weakness, and regulatory risks tempered my enthusiasm.